A new urine test, MPS2-AS, shows promise for detecting aggressive prostate cancers in men on active surveillance, potentially reducing the need for repeated biopsies. The test is based on the FDA-approved MyProstateScore 2.0 (MPS2) assay and can identify tumors at Grade Group 3 (Gleason 4+3) or higher, the threshold at which treatment is generally recommended. In a study of 223 men undergoing surveillance biopsies, the MPS2-AS test correctly detected 93% of higher-grade tumor

Prostatitis refers to inflammation of the prostate gland and is categorized into acute bacterial prostatitis, chronic bacterial...

Prostate cancer is the most commonly diagnosed malignancy in men worldwide. It is the fifth leading cause of cancer-related deaths in...

Benign Prostatic Hyperplasia is a noncancerous enlargement of the prostate gland, commonly seen in aging men. It can lead to urinary...